TrialPath
ALS (Lou Gehrig's disease) · Atlanta

ALS (Lou Gehrig's disease) clinical trials in Atlanta

7 recruiting amyotrophic lateral sclerosis studies within range of Atlanta. Click any trial for full eligibility criteria and contact info.

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Recruiting

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

PhasePhase 3
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 55 more
SponsorPrilenia
▾Tap for details
Apply

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

PhasePhase 2
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 48 more
SponsorZydus Therapeutics Inc.
▾Tap for details
Apply

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041 · Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Recruiting

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereSacramento, California, United States + 5 more
SponsorLeigh R. Hochberg, MD, PhD.
▾Tap for details
Apply

Tofersen in Non-SOD1 ALS

Recruiting

The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are: * Does tofersen lower the levels of neurofilament light chain (NfL) in the blood and CSF of adult participants with non-SOD1 ALS? * Is tofersen safe and tolerable for adult participants with non-SOD1 ALS? * Does tofersen affect other measurements such as clinical outcomes and quality-of-life measures in participants with non-SOD1 ALS? Participants will : * Receive 100mg tofersen via lumbar puncture for 24 weeks. The doses are at the following time points: Weeks 0, 2, 4, 8, 12, 16, 20, and 24. * Complete 2 follow-up visits following the end of the dosing period at Weeks 28 and 32. * Complete a variety of questionnaires and outcome measurements such as strength and breathing testing.

PhasePhase 2
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States + 2 more
SponsorWashington University School of Medicine
▾Tap for details

The National Amyotrophic Lateral Sclerosis Registry

Recruiting

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Phase—
TypeObservational
Age18 Years
WhereAtlanta, Georgia, United States
SponsorCenters for Disease Control and Prevention
▾Tap for details
Apply

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 · Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 25 more
SponsorMayo Clinic
▾Tap for details
Apply

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034 · Adjustment Disorder
Recruiting

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereBirmingham, Alabama, United States + 32 more
SponsorReunion Neuroscience Inc
▾Tap for details
Apply